- |||||||||| Enrollment change, Trial termination, Trial primary completion date: 2-StaLi: Cognitive Outcome After Two-stage Liver-Operation (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=23, Terminated, Active, not recruiting --> Completed | Initiation date: Sep 2010 --> Jun 2011 | Trial primary completion date: Dec 2017 --> Dec 2016 N=40 --> 23 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2017
- |||||||||| donanemab (LY3002813) / Eli Lilly
Trial completion, Trial primary completion date: A Study of LY3002813 in Participants With Alzheimer's Disease (clinicaltrials.gov) - Dec 26, 2017 P1, N=100, Completed, Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2016
- |||||||||| midazolam hydrochloride / Generic mfg.
Trial initiation date, Trial primary completion date, Surgery: Decreasing the Incidence of Delirium After Cardiac Surgery (clinicaltrials.gov) - Dec 7, 2017 P4, N=200, Not yet recruiting, Phase classification: P1/2 --> P=N/A | N=54 --> 82 Initiation date: Jan 2016 --> Jan 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: LESCOD: "Lewy Body Screening in Cognitive Disorders" (clinicaltrials.gov) - Dec 7, 2017
P=N/A, N=133, Terminated, Initiation date: Jan 2016 --> Jan 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 N=180 --> 133 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Aug 2017; recruitment problems
- |||||||||| Trial primary completion date: 18F-AV-1451 High Resolution Autopsy Study (clinicaltrials.gov) - Nov 30, 2017
P1, N=10, Active, not recruiting, Enrolling by invitation --> Completed | N=80 --> 58 Trial primary completion date: Oct 2017 --> Mar 2018
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Retinal Neurodegenerative Signs in Alzheimer's Diseases (clinicaltrials.gov) - Nov 13, 2017
P=N/A, N=200, Completed, Active, not recruiting --> Completed Recruiting --> Completed | N=300 --> 200 | Trial primary completion date: Jun 2015 --> Jun 2014
- |||||||||| Trial completion: Cataract Removal and Alzheimer's Disease (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=122, Completed, Recruiting --> Completed | N=300 --> 200 | Trial primary completion date: Jun 2015 --> Jun 2014 Active, not recruiting --> Completed
- |||||||||| Trial completion, Trial primary completion date, IO biomarker: IMABio3: Central and Systemic Inflammation in Alzheimer's Disease (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=125, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Apr 2017
- |||||||||| Trial completion, Enrollment change: Imaging of Cognition, Learning, and Memory in Aging (clinicaltrials.gov) - Nov 1, 2017
P=N/A, N=294, Completed, Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Apr 2017 Recruiting --> Completed | N=550 --> 294
- |||||||||| fluoxetine / Generic mfg.
Phase classification: Fluoxetine Prevention Trial (clinicaltrials.gov) - Oct 31, 2017 P1, N=376, Not yet recruiting, Phase classification: P=N/A --> P3 Phase classification: P=N/A --> P1
- |||||||||| Enrollment closed: 18F-AV-1451 High Resolution Autopsy Study (clinicaltrials.gov) - Oct 13, 2017
P1, N=10, Active, not recruiting, N=880 --> 150 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Mar 2016; It was difficult to secure enrollment of the targeted number of subjects. Recruiting --> Active, not recruiting
|